|
I sing in a choir http://www.autoandmotorfun.com/stmap_9b680.html?viagra.diarex.sustinex mind lab pro review The debate has sprung from a clinical trial that aims to see whether low-dose stavudine, or d4T, is as effective as tenofovir, or TDF, one of the antiretrovirals (ARVs) currently recommended for first-line HIV treatment by the World Health Organisation (WHO). d4T was long used as the primary first-line therapy but harsh side effects, including neuropathy (nerve damage) and lipodystrophy (abnormal, sometimes disfiguring, fat distribution), led the WHO to recommend against its use in 2011.It suggested that TDF or zidovudine (AZT) be used instead. But both drugs are relatively expensive: according to the health advocacy organisation, Médecins Sans Frontières (MSF), d4T is available for as little as $20 (R204) a patient a year, compared with $75 (R764) a patient a year for AZT and $57 (R581) a patient a year for TDF.ÂÂ
|